Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP cut its holdings in Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 87.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,800 shares of the company's stock after selling 74,800 shares during the quarter. Two Sigma Advisers LP owned approximately 0.07% of Sensus Healthcare worth $75,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new position in Sensus Healthcare in the fourth quarter worth about $27,000. Barclays PLC bought a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $35,000. BNP Paribas Financial Markets purchased a new stake in Sensus Healthcare during the fourth quarter valued at approximately $47,000. IFP Advisors Inc acquired a new stake in Sensus Healthcare in the fourth quarter valued at approximately $95,000. Finally, NewEdge Advisors LLC acquired a new stake in Sensus Healthcare in the fourth quarter valued at approximately $109,000. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded down $0.13 during midday trading on Thursday, hitting $4.97. The company's stock had a trading volume of 61,572 shares, compared to its average volume of 197,467. The firm has a market cap of $81.73 million, a P/E ratio of 12.43 and a beta of 1.32. The firm's 50 day moving average is $4.65 and its 200-day moving average is $5.81. Sensus Healthcare, Inc. has a fifty-two week low of $4.01 and a fifty-two week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). The company had revenue of $8.34 million for the quarter, compared to analysts' expectations of $7.23 million. Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. As a group, analysts forecast that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SRTS. Maxim Group decreased their price objective on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price objective on shares of Sensus Healthcare in a research report on Friday, April 4th. Lake Street Capital dropped their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Finally, Wall Street Zen cut shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $11.67.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.